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A role for PrP in the toxic effect of oligomeric forms of Aβ, implicated in Alzheimer’s disease 
(AD), has been suggested but remains controversial. Here we show that PrP is required for 
the plasticity-impairing effects of ex vivo material from human AD brain and that standardized 
Aβ-derived diffusible ligand (ADDL) preparations disrupt hippocampal synaptic plasticity in a 
PrP-dependent manner. We screened a panel of anti-PrP antibodies for their ability to disrupt 
the ADDL–PrP interaction. Antibodies directed to the principal PrP/Aβ-binding site and to 
PrP helix-1, were able to block Aβ binding to PrP suggesting that the toxic Aβ species are of 
relatively high molecular mass and/or may bind multiple PrP molecules. Two representative 
and extensively characterized monoclonal antibodies directed to these regions, ICSM-35 and 
ICSM-18, were shown to block the Aβ-mediated disruption of synaptic plasticity validating 
these antibodies as candidate therapeutics for AD either individually or in combination. 
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S
oluble  non-fibrillar  forms  of  amyloid  β-protein  (Aβ)  have 
been implicated in, and shown to correlate with, disease pro-
gression in animal models of Alzheimer’s disease (AD) and   
patients  with  AD1.  Low  nanomolar  concentrations  of  synthetic   
Aβ are known to disrupt synaptic plasticity in vivo and in vitro, 
but  the  conformation  and  size  of  the  Aβ  species  responsible 
remain unclear2–5. It has recently been reported that the prion pro-
tein (PrPC) can function as a cellular receptor for a preparation of   
synthetic Aβ referred to as Aβ-derived diffusible ligands (ADDLs) 
and that PrPC is required for the disruption of synaptic plastic-
ity mediated by ADDLs6. Nanomolar affinity of binding has been 
reported7–9  and  a  single  anti-PrP  monoclonal  antibody  with  an 
epitope  around  residues  95–105  blocked  ADDL  binding  and   
toxicity6. In further studies, constitutive knockout of PrPC expres-
sion reversed several pathological phenotypes in a mouse model   
of AD10 as did peripheral treatment of the same mouse model with 
an anti-PrP antibody11.
If  confirmed,  such  a  finding  is  of  considerable  importance   
given the extensive investigation of targeting PrPC for prion disease   
therapeutics12. In particular, the abolition of neuronal PrP expres-
sion  in  the  adult  murine  nervous  system  is  without  serious   
consequence13,14  and  both  small  molecule12  and  monoclonal   
antibody  therapeutics15  have  been  extensively  studied.  Indeed   
therapeutic  molecular  interactions  with  PrPC  have  been  charac-
terized  and  fully  humanized  anti-PrP  monoclonal  antibodies   
have been produced for clinical studies in human prion disease16,17.
However, a number of groups have since reported deleteri-
ous effects of Aβ that do not require PrP expression7,8,18. In this 
context, it is important to recognize that a range of different Aβ 
preparations have been used and that this may in part explain 
some of the conflicting reports. Moreover, discrepancies between 
animal, tissue, cellular and biochemical AD models with respect 
to a possible role for PrPC are to be anticipated. AD is a hetero-
geneous disease and perhaps better considered to be a clinico-
pathological syndrome with multiple genetic and environmen-
tal factors involved in its aetiology and progression. The many 
reported animal models of AD each recapitulate only part of this 
syndrome. Even if PrPC is indeed an important receptor for toxic 
Aβ species, it would not be reasonable to expect PrPC ablation   
to rescue all aspects of pathology in each model. Further, given 
that the concentration of the active species is not known and   
may differ between studies by different groups some effects may 
be due to higher Aβ concentrations, which could elicit nonspecific 
toxic effects.
We first sought to repeat the studies of Laurén et al.6 on syn-
aptic  plasticity,  using  congenic  wild-type  and  PrP  null  lines,  to 
confirm  the  PrP-dependence  of  the  toxicity  of  our  ADDLs  and 
to  characterize  the  putative  PrP:Aβ  interaction.  Given  the  poor   
characterization and variable toxicity of different Aβ preparations, 
we were careful to use only formulations which caused impairment of   
long-term potentiation (LTP) and conformed to defined biophysi-
cal  criteria  consistent  with  previous  descriptions  of  ADDLs3,6,19. 
However, as it is unclear whether Aβ species similar to those found 
in ADDL preparations are present in human brain, we considered 
it essential to also determine if PrPC was required for the synaptic 
plasticity-impairing effects of AD brain-derived Aβ. Thereafter, we 
proceeded to further studies aimed at characterization of the puta-
tive therapeutic target and approaches to block PrP:Aβ interaction 
and its effects on synaptic plasticity.
We  confirmed  that  well-characterized  ADDL  preparations   
inhibit LTP in a PrP-dependent manner and that the block of LTP 
mediated by the most disease-relevant form of Aβ, Aβ extracted 
from  AD  brain,  requires  expression  of  PrP.  We  also  report  the   
development  of  a  high-throughput  screen,  which  allowed  us  to 
identify antibodies that recognize certain epitopes contained both 
within  and  outside  the  previously  characterized  Aβ:PrP-binding 
site. Notably, antibodies to helix-1 of PrP, prevented ADDL bind-
ing to PrP and the block of LTP mediated by both ADDLs and   
AD brain-derived Aβ.
Results
Characterization  of  reproducible  preparations  of  ADDLs.  We 
used a standardized procedure to generate ADDL preparations from 
Aβ1 − 42 or bADDL preparations from biotinylated Aβ1 − 42 (bAβ1 − 42) 
and then assessed the consistency of the species produced using a 
battery of biophysical tests. Both unmodified and biotinylated Aβ 
were used to confirm that biotinylation did not fundamentally alter 
the  properties  of  the  oligomers.  Size-exclusion  chromatography 
(SEC) using three different running buffers showed that both ADDLs 
and bADDLs had highly similar profiles producing two prominent 
peaks (Fig. 1a; Supplementary Fig. S1). The first peak eluted in the 
void volume and the second eluted in a volume consistent for Aβ 
monomer20. Moreover, both peaks had trailing and leading shoulders 
suggesting the presence of low abundance oligomers intermediate in 
size between Aβ monomer and the void material. Given the limited 
size resolution of SEC, and the possibility of forming artefacts owing 
to non-ideal interactions with the column, we also analysed our 
bADDL preparations using a solution-based technique, analytical 
ultracentrifugation  (AUC)  (Fig.  1b).  Sedimentation  of  bADDLs 
occurred in two distinct phases containing ~60 and 40% of the 
material, respectively. The initial sedimentation contained a mixture 
of species with calculated masses ranging from 90 to 400,000 and 
accounted for around 60% of the peptide. The slowly sedimenting 
portion contained a single species with calculated molecular weight 
of 5–6,000 close to the value expected for monomeric, biotinylated 
Aβ  peptide.  In  agreement  with  the  SEC  results,  the  AUC  data 
confirm that bADDL preparations are heterogeneous and include 
Aβ monomer, small amounts of low n-oligomers and species with 
calculated masses  > 90,000. It is noteworthy that in all samples tested 
bADDL preparations contained slightly greater amounts of high-
molecular-weight species than did ADDLs (Fig. 1a; Supplementary 
Fig. S1). Consistent with other biophysical assessments, negative-
stain electron microscopy (EM) confirmed that ADDL and bADDL 
preparations contained a mixture of different sized species, ranging 
from globular structures of 8–12 nm diameter and flexible rods of 
15–60 nm in length and 5–10 nm diameter (Fig. 1c,d; Supplementary 
Fig.  S2).  These  structures  are  reminiscent  of  those  detected  by 
Laurén et al.6, but are in contrast to the entirely globular structures 
observed by Chen et al.9 and Balducci et al. when prepared using 
simple phosphate buffer7. The species detected by SEC, AUC and 
EM were SDS-labile and migrated on SDS–PAGE predominantly as 
monomer (Fig. 1e,f), however, a small amount of higher molecular 
weight Aβ species were detected if samples were not boiled before 
SDS–PAGE and proteins visualized by western blotting. As a major 
factor  which  we  have  found  to  influence  production  of  ADDL 
preparations of consistent composition is the effective solubilization 
of hexafluoro-2-propanol (HFIP)-treated Aβ, we used SDS–PAGE 
and silver staining as a simple means to measure the total amount 
of Aβ present in all our ADDL preparations. These experiments 
revealed that the actual concentration of total Aβ in our ADDL 
preparations varied between 70 to 90 µM (based on the molecular 
weight of Aβ monomer), less than the 100 µM concentration based 
on the starting amount of Aβ used.
AD brain-derived Aβ inhibits LTP in a PrP-dependent manner. 
Having  established  procedures  to  produce  and  characterize  our 
bADDL and ADDL preparations, we sought to assess their effect 
on synaptic plasticity and to determine whether this effect required 
expression of PrP. As expected, both our bADDL and ADDL prep-
arations  significantly  inhibited  LTP  in  hippocampal  slices  from 
wild-type FVB/N and C57Bl/6J mice (P < 0.01, one-way analysis 
of variance (ANOVA), Fig. 2a; Supplementary Fig. S3). Using an ARTICLE     
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FVB/N congenic PrP null mouse line we next investigated whether 
this Aβ-mediated inhibition of LTP required the expression of PrP. 
As in a previous study using another PrP null mouse model6, bAD-
DLs that blocked LTP in wild-type mice failed to impair LTP in the   
hippocampi of our PrP null mice (Fig. 2b). Although these results 
suggest a potential role for PrP in bADDL-mediated depression of 
hippocampal LTP, it is not clear if such preparations include Aβ 
species that occur in AD brain. Therefore, we sought to determine 
whether water-soluble extracts of AD brain that contain SDS-stable 
Aβ dimers also required the expression of PrP for their plasticity-
impairing effects. For these experiments, we used a brain extract 
from a non-demented control subject that lacked detectable Aβ and 
a Tris-buffered saline (TBS) extract from an AD brain that contained 
significant amounts of Aβ monomer and SDS-stable dimer (Fig. 2c).   
As  in  earlier  experiments21,  the  Aβ-containing  extracts  potently 
inhibited LTP in slices from FVB/N mice (Fig. 2d, P < 0.01, one-
way ANOVA), whereas TBS extracts that lacked Aβ had no effect   
(Fig. 2d). Importantly, as was the case with bADDLs (Fig. 2b), the 
block of LTP mediated by brain-derived Aβ required the expression 
of PrPC, with the AD-TBS extract unable to alter LTP in hippocam-
pal slices from PrP null mice (Fig. 2d). As expected, application of 
TBS extract from a control brain, that lacked detectable amounts 
of Aβ, had no effect on LTP in slices from either PrP expressing 
or PrP null FVB/N mice (Fig. 2d and 168 ± 10% versus 164 ± 10%, 
respectively). These findings provide important evidence that PrP   
is required for the plasticity-impairing effects of pathogenically rele-
vant brain-derived Aβ species and suggest that PrP may be required 
for the changes in synaptic function that characterize the earliest 
stages of AD22. As yet, it is unclear as to how the active Aβ species in 
human brain relate to the active species present in an Aβ preparation   
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Figure 1 | Biophysical characterization of A species present in the bADDL preparation. (a) Size-exclusion chromatography of two different batches 
of freshly prepared ADDLs and bADDLs eluted in PBS showing the ratio of oligomeric (left) to monomeric (middle) Aβ, as well as a buffer peak (right). 
(b) Velocity analytical ultra centrifugation of freshly prepared bADDLs in Ham’s F12 medium as detected by absorbance at 280 nm and represented 
by continuous distribution c(s), the sedimentation coefficient distribution. The monomer (calculated molecular mass 5,000–6,000) and the oligomer 
components (calculated molecular mass 90,000–400,000) have been coloured blue and red, respectively. (c, d) Negatively stained transmission electron 
micrograph of (c) bADDLs and (d) ADDLs showing a mixture of globular and rod-like structures  < 100 nm in length. Scale bar, 50 nm. (e, f) SDS–PAGE of 
ADDL preparations analyzed by silver staining (e) to estimate the amount of soluble Aβ present in three different ADDL preparations (labelled 1, 2 and 3) 
and western blot analysis (f) using the N-terminal anti-Aβ antibody, 6E10, to identify low abundance SDS-stable Aβ species. Two different concentrations 
of each test sample (10 µM and 20 µM, for Silver stain and 1 µM and 2 µM for western blot) were examined.ARTICLE
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such as ADDLs. It is worth pointing out that both sources are hetero-
genous, ADDLs contain a mixture of different sized Aβ species 
ranging from monomer to ~2 MDa19 and the water-soluble extract 
of AD brain contains Aβ ranging from monomer to ≥ 70 kDa21.   
In the case of water-soluble brain extracts, fractions rich in SDS-
stable dimers have been shown to mediate synaptotoxicity, however, 
whether this activity is mediated by discrete Aβ dimers, or assem-
blies built from SDS-stable dimers is not clear21,23. Indeed, we have 
recently shown that synthetic Aβ dimers alone are not synaptotoxic, 
but must assemble into larger pre-fibrillar Aβ structures to perturb 
synaptic plasticity23. Thus, although we cannot yet provide a direct 
comparison of the biophysical properties of brain-derived Aβ and 
the polydisperse collection of assemblies that constitute ADDLs, it is 
remarkable that both ADDLs and human brain-derived Aβ require 
the expression of PrP to exert their toxic effects.
PrP/ADDL interaction can be targeted at multiple sites. Having   
established  the  requirement  for  PrP  for  the  plasticity-impairing 
activity  of  both  AD  brain-derived  Aβ  and  ADDLs,  we  then  set   
out  to  investigate  whether  active  preparations  of  Aβ  bound  to 
PrP. Previous characterization of the PrP:Aβ interaction has been   
carried out using preparations of synthetic Aβ that acted in a PrP-
independent manner7, had not been shown to be toxic8,9 or were 
studied  at  micromolar  concentrations7,9.  We  probed  the  interac-
tion using a high-throughput plate-based DELFIA (dissociation-
enhanced lanthanide fluorescent immunoassay). A binding response 
between huPrP23 − 231 and either bADDLs or ADDLs was detected at 
low nanomolar concentrations with apparent dissociation constants 
for total Aβ of 82 ± 7 and 100 ± 30 nM, respectively (Fig. 3a), with 
no indication of a tight-binding component (Methods). Given that 
the total concentration of Aβ present in our stock solution was on 
average 20% less than the 100 µM value derived from the weight 
of starting peptide powder, that a significant portion of the peptide 
remained as monomer (Fig. 1a,b), and that the molar concentration 
of Aβ oligomers must (because of their higher molecular weight) 
be lower than the concentration based on monomer content, it is 
evident that one or more of the species present in ADDL prepa-
rations binds PrP very tightly, probably in the picomolar range. In 
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Figure 2 | PrPC is required for the inhibition of LTP by bADDLs and A-containing extracts of human brain. fEPSPs were recorded from the CA1 region 
of the hippocampus in all cases. Insets show example fEPSP traces before and 1 h post theta-burst (TB) stimulation (stimulus artefact was removed for 
clarity). P values were calculated using one-way ANoVA and the Tukey–Kramer post hoc test. (a) Extracellular recordings from FVB/N mice show stable 
LTP measured up to 1 h post-TB (black squares, 184 ± 15%, n = 7). Pretreatment of the slices with bADDLS for 30 min before TB caused a significant 
inhibition of LTP (red circles, 109 ± 10%, P < 0.01, n = 6). (b) LTP was reliably induced in slices from PrP null mice treated with vehicle control (black squares, 
151 ± 8%, n = 6). Significantly, perfusion of slices from PrP null mice with the same bADDL preparation used in a, did not impair LTP (red circles, 149 ± 11%, 
n = 5, P > 0.05). (c) Immunoprecipitation/western blot analysis of brain extracts revealed the presence of abundant Aβ monomer (M) and  
SDS-stable dimer (D) in a sample taken from an AD brain and the complete absence of Aβ in an extract from a non-demented control subject 
(Ctrl). Estimates of Aβ concentration indicate the presence of 14 and 3.2 ng ml − 1 of monomer and SDS-stable dimer, respectively. Nonspecific (NS) 
immunoreactive bands were detected when Tris-buffered saline (TBS) alone was immunoprecipitated. Molecular weight markers are on the left.  
(d) Perfusion of slices from wild-type FVB mice with AD brain for 30 min before TB significantly impaired LTP (red circles, 116 ± 9%, n = 6) compared with 
slices perfused with control brain extract (black squares, 153 ± 8%, n = 6, P < 0.05). In contrast, treatment of slices from PrP − / −  mice with AD brain extracts  
failed to alter LTP (grey triangles, 164 ± 10%, n = 6, P > 0.05). *Refers to when perfusion of bADDLs/AD brain extract was started and arrow denotes 
application of TB. The numbers on the example EPSPs (insets) represent the time points of the average fEPSP slope values indicated with the same 
numbers. All values are mean ± s.e.m. Scale bar on insets denotes 1 mv, 5 ms.ARTICLE     
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Figure 3 | bADDLs avidly bind PrP in a manner that can be blocked by certain anti-PrP antibodies. (a) Dose response curves of ADDLs (green)  
and bADDLs (red) to plate-bound full-length PrP or background wells coated with BSA (light green and red for ADDLs and bADDLs, respectively).  
(b) Binding of 100 nM bADDLs to huPrP23 − 231, huPrP91 − 231 and huPrP119 − 231. (c) Competition of binding of bADDLs to surface-bound huPrP23 − 231 by different 
constructs of PrP. (d) Inhibition of bADDL binding to huPrP23 − 231 by ICSM-35 after pre-incubation of surface-bound huPrP23 − 231 with ICSM-35.  
(e) Screen of the ICSM panel of antibodies using a high throughput DELFIA to detect bADDL or antibody binding. Antibodies are classed in different 
binding regions 95–105 (red), 131–153 (yellow), structured region (magenta) or undefined epitopes (blue). ICSM-18 and ICSM-35 are highlighted.  
Surface-bound huPrP23 − 231 was pre-incubated for 1 h with 100 nM antibodies and then incubated for 1 h with or without 100 nM bADDLs before detection 
with either Eu-N1 streptavidin or Eu-N1 anti-mouse antibody. (f, g) Model of the PrP/ICSM-18 complex (f) based on the published crystal structure and 
with the antibody extension built in with PrP and the ICSM-18 epitope (yellow) highlighted; (g) Modelled structure of the PrP/Aβ interaction with Aβ 
spheroids (green), PrP (magenta), the ICSM-18 epitope (yellow) and the unstructured ICSM-35 epitope (red) built in, highlighting the large distance 
between Aβ-binding site and the ICSM-18 epitope. All graphs show mean ± s.d. and are an average of at least three data points.ARTICLE
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contrast, Aβ monomer exhibited no binding to PrP at concentration 
≤ 3×10 − 7 M (Supplementary Fig. S4). Nonspecific oligomer binding 
to a background BSA surface was observed for both ADDLs and 
bADDLs when the concentration was raised from high nanomolar to 
low micromolar, highlighting the importance of probing this inter-
action in the nanomolar range using well-defined Aβ preparations. 
Moreover, the modest binding observed when micromolar concen-
trations of monomer were used likely resulted because spontaneous 
aggregation of Aβ occurs in this concentration range23 and, once 
formed, such aggregates could bind to PrP. Consequently, all subse-
quent experiments were carried out using bADDLs at a concentra-
tion of 100 nM (monomer equivalent Aβ) where the most specific 
interaction could be measured. Given that both PrP24 and Aβ25 are 
known to contain high-affinity for copper-binding sites in relevant 
positions, the possibility that their interaction may be mediated by 
copper chelation was investigated. Addition of up to 10 mM EDTA 
did not change the level of bADDL binding (Supplementary Fig. S5).   
At  these  concentrations,  EDTA  should  be  capable  of  displacing   
copper from both PrP and Aβ26 thus excluding simple, nonspecific 
copper chelation as the mechanism for the PrP:Aβ interaction.
The binding to different length constructs of PrP showed that 
huPrP91 − 231 bound similar quantities of bADDLs, as did the full-
length construct, suggesting the crucial high-affinity-binding site 
was  not  in  the  region  23–91  (Fig.  3b).  In  contrast,  huPrP119 − 231 
displayed almost no binding, confirming the role of the 91–119 
region in the high-affinity PrP:Aβ interaction. A competition assay, 
whereby increasing concentrations of the different PrP constructs 
were co-incubated with bADDLs to prevent binding to surface-
bound huPrP23 − 231, confirmed that the interaction could occur in 
solution and revealed that while the region 23–90 did not appear to 
contain a separate high-affinity-binding site, it was indeed involved 
in modulating the high-affinity interaction (Fig. 3c).
We then tested the ability of the antibody ICSM-35, which binds 
to an epitope contained in residues 95–105 of PrP27, the putative site 
of ADDL binding6 for ability to block the PrP:Aβ interaction. This 
antibody blocked binding of bADDLs to PrP in a classical dose-
dependent manner with an IC50 = 10.4 ± 1.7 nM (Fig. 3d). A screen of 
28 PrP-binding antibodies pre-incubated with PrP before the addi-
tion of bADDLs showed that all antibodies that bound fully to PrP 
were capable of blocking bADDL binding, at least in vitro, although 
their efficacy varied (Fig. 3e). The differences in efficacy were clearly 
epitope dependent, with those interacting directly with the putative 
ADDL-binding site most effective, followed by those that bind to 
helix-1 of PrP, whereas those binding to other structured regions of 
the protein were the least effective. There was no epitope-dependent 
correlation between the level of antibody binding and the level of 
inhibition, although, as expected, individual antibodies that failed 
to remain bound to PrP did not inhibit bADDL binding. Further-
more, the two best characterized antibodies that bind to helix-1 and 
the 95–105 epitope (ICSM-18 and ICSM-35, respectively), both bind 
to full-length human prion protein with affinities of ~10 nM, block 
ADDLs with inhibition constants of ~20 nM, yet still differ in the 
magnitude of their inhibition (Supplementary Fig. S4). ICSM-18 and 
ICSM-35 were chosen for further characterization as representative 
members of the groups that bind to helix-1 and the 95–105 epitope, 
respectively, because of their proven efficacy as anti-prion therapeu-
tics and they do not cause acute toxicity15. Moreover, the structure of 
the PrP:ICSM-18 complex has been solved at atomic resolution16.
The ability of ICSM-18 to block the interaction, despite binding 
to an epitope far-removed from the 95–105 segment, is surprising 
(Fig. 3f,g). It is unlikely that the on-rate of PrP with the Aβ is reduced 
significantly by linking with the antibody, as the enlarged structure 
will diffuse only slightly more slowly. The dissociation rate of PrP 
from the Aβ structure is not likely to increase by linking interac-
tions with the antibody owing to bulk-solvent effects. The antibody 
is also unlikely to cause disruption of the water structure or dielec-
tric properties around the PrP:Aβ interface; hence, hydrophobic   
or electrostatic interactions will be largely unaffected. However, if 
PrP:PrP contact is needed to stabilize the PrP layer adhered to the 
Aβ aggregates, then interaction with the antibody would certainly 
prevent  this  and  weaken  the  system.  Multiple  PrP-binding  sites 
would suggest the bound Aβ assemblies contains a repeat struc-
ture. It may be that such antibodies prevent the binding of larger Aβ 
assemblies but not smaller species. Likewise, reorganization of the 
protein on the membrane surface could bring these epitopes into 
close proximity allowing ICSM-18 to sterically block the interaction, 
although this is unlikely to be the cause of the effect in a plate-based 
biochemical assay and would not explain the stronger inhibition of 
helix-1-directed antibodies compared with those that bind to struc-
tured areas closer to the Aβ oligomer-binding site. Either option 
opens up the possibility of using multiple antibodies to therapeuti-
cally block this interaction. Moreover, these results validate the use 
of this novel high throughput system as a useful first round screen to 
identify candidate therapeutics capable of inhibiting or modulating 
ADDL binding to PrP.
Antibodies block the A-mediated disruption of LTP in vivo. 
To further assess the potential of two lead monoclonal antibodies 
identified in our screen, and that belong to the two groups of anti-
bodies that most effectively blocked ADDL binding to PrP in vitro  
(Fig. 3e), we examined whether these antibodies could also block 
Aβ-mediated  impairment  of  synaptic  plasticity.  To  ensure  the   
effect was not just present in FVB/N mice, this part of the study was 
carried out using hippocampal slices from C57Bl/6J mice. Perfusion 
of slices from C57Bl/6J mice with ADDLs 30 min before LTP induc-
tion significantly depressed LTP compared with slices treated with 
buffer control alone (Fig. 4a, P < 0.01, one-way ANOVA), whereas 
previous  application  of  low  concentrations  of  the  anti-PrP  anti-
body, ICSM-35 (2 µg ml − 1, 13 nM) abolished the ADDL-mediated 
impairment of LTP (Fig. 4a, P < 0.01, one-way ANOVA). Similarly, 
when slices were incubated with ICSM-18 20 min before ADDLs 
this antibody also protected against the ADDL-mediated block of 
LTP (Fig. 4b, P < 0.01, one-way ANOVA). Importantly, both ICSM-
18 and ICSM-35 had no significant effect on LTP when adminis-
tered alone (Supplementary Fig. S6a,b). ICSM-35 is directed against 
amino acids 93–102 of PrPC, which includes the Aβ:PrP-binding 
domain identified in this and previous studies6, whereas ICSM-18 
selectively binds to helix-1 of PrP16. Thus, unlike ICSM-35, which 
should directly target the ADDL-binding site, ICSM-18 may act by 
hindering formation of the PrP:Aβ interaction.
Having found that anti-PrP antibodies prevented ADDL-medi-
ated inhibition of LTP in mouse hippocampal slices, next we exam-
ined the in vivo efficacy of one of the antibodies, ICSM-18, in a dif-
ferent species, the rat. This would confirm if the PrP-dependence 
of Aβ toxicity was species, as well as mouse strain, independent. 
We directly compared the ability of ICSM-18 with an IgG1 isotype 
control antibody to abrogate the inhibition of hippocampal LTP 
by  the  pathophysiologically  relevant  Aβ-containing  TBS  extract 
of AD brain. In addition, to confirm that the involvement of PrP 
was not limited to extracts from a single AD brain, we used extracts 
from different AD and control brains than those used in Figure 2d. 
Intracerebroventricular (i.c.v.) pre-injection of the anti-PrP anti-
body completely prevented the AD brain Aβ-mediated inhibition 
of high-frequency stimulation (HFS)-induced LTP. In contrast, ani-
mals injected with AD brain extract immunodepleted of Aβ (Sup-
plementary Fig. S7) no longer blocked LTP (131 ± 6, n = 6; P < 0.05 
compared with baseline, paired t-test; P > 0.05 compared with vehi-
cle-injected  controls  at  3 h,  one-way  ANOVA,  data  not  shown). 
Thus, acute administration of soluble extract from AD brain (5 µl, 
i.c.v.; Fig. 4c) completely inhibited LTP at 3 h post-HFS in an Aβ-
dependent manner in animals injected 30 min previously with the 
control antibody (30 µg in 10 µl, i.c.v.; P > 0.05 compared with base-ARTICLE     
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line, paired t-test; P < 0.05 compared with controls that received two 
vehicle injections, one-way ANOVA). In contrast, in animals that 
were pre-injected i.c.v. with ICSM-18 (30 µg) HFS induced robust 
LTP (P < 0.05 compared with baseline (paired t-test) and compared 
with AD brain Aβ + control IgG1, one-way ANOVA) that was simi-
lar in magnitude to controls (P > 0.05, one-way ANOVA). When 
injected alone, neither ICSM 18 nor the control IgG1 significantly 
affected the magnitude of LTP (Supplementary Fig. S6c). The find-
ing that sequence-selective targeting of PrP using antibodies can 
ameliorate  the  plasticity-impairing  activity  of  AD  brain-derived 
material in rats in vivo corroborates our in vitro finding with ADDLs 
and strongly encourages further exploration of this approach as an 
attractive therapeutic strategy.
Discussion
These data support the earlier finding that PrPC functions as a recep-
tor for mediating toxicity of certain Aβ species. That the inhibitory 
effect of ADDLs on synaptic plasticity is PrPC-dependent has been 
confirmed using in vitro LTP recordings from congenic wild-type 
and PrP null mice and importantly that PrP expression is required 
for the plasticity-impairing activity of human brain-derived Aβ. 
There  has  been  much  debate  about  the  nature  of  biologically   
relevant  Aβ  oligomers.  Here  we  used  two  distinct  preparations, 
one prepared from synthetic Aβ1 − 42 to form ADDLs, and which 
we were careful to confirm to be biologically active and the other 
derived from the water-soluble phase of human AD brain. By using 
ADDLs, which are known to be active and to have similar biophysi-
cal characteristics as those used by Lauren et al, we could test the 
veracity of earlier reports that Aβ toxicity was mediated (at least 
in part) through PrP. Importantly, both preparations inhibited LTP 
in a PrP-dependent manner, suggesting that the ADDL preparation 
contained a component with similar properties to those found in 
AD brain. Heterogeneous preparations of Aβ aggregates are known 
to have nonspecific cytotoxicity at high concentrations and it would 
therefore be incorrect to interpret a failure of PrP targeting to amel-
iorate such nonspecific toxicity as excluding a role for PrP in Aβ-
mediated neurotoxicity. Therefore, to expect PrP ablation to block 
toxicity in all aspects of all models would be to oversimplify a com-
plex problem. The dependence of toxicity on particular receptors in 
individual animal models of AD may allow us to ascertain which 
models correctly mimic particular aspects of AD.
A number of synaptic proteins have been shown to affect the 
binding and toxic effects of Aβ. mGluR5 was shown to affect binding 
of Aβ oligomers to excitatory synapses with anti-mGluR5 antibod-
ies reducing Aβ oligomer binding by 50% (ref. 28). This is a similar 
level of reduction shown by PrP6. Although the affect of this receptor 
on Aβ binding was directly visualized, a binary interaction between 
Aβ and mGluR5 has not been proven. EphB2 was recently shown 
to co-precipitate with cell-derived Aβ and the fibronectin-repeat 
domain was shown to be critical29. Again, a direct binary interac-
tion has not been proven. The LTP deficit in the J20 mouse model 
of AD, caused by downregulation of N-methyl-d-aspartate receptor, 
was reversed by overexpressing EphB2 and it would be interesting 
to see if this also applies to exogenous human brain-derived Aβ or 
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Figure 4 | Inhibition of LTP by ADDLs or A-containing AD brain extract is 
ameliorated by the anti-PrPC antibodies ICSM-35 and ICSM-18.  
(a) Conditioning stimulation in hippocampal slices from C57Bl/6J mice 
treated with vehicle solution induced a robust LTP (black squares, 152 ± 7%, 
n = 6), whereas pretreatment (30 min) with ADDLs significantly depressed 
LTP (red circles, 115 ± 5%, n = 8, P < 0.01). In contrast, perfusion of slices with 
the anti-PrP antibody, ICSM-35 (which recognizes an epitope within the 
residues 93–102; 2 µg ml − 1), 20 min before application of ADDLs prevented 
the impairment of LTP caused by ADDLs (grey triangles, 151 ± 9%, n = 6, 
P > 0.05). P values were calculated using one-way ANoVA and the Tukey–
Kramer post hoc test. (b) As in a above, but ICSM-18 (which recognizes 
an epitiope within residues 143–153 of PrP) was used in place of ICSM-
35. Like ICSM-35, ICSM-18 (grey triangles, 157 ± 9%, n = 6) completely 
ameliorated the inhibitory activity of ADDLs (P < 0.01). #Refers to perfusion 
of ICSM18/35; *refers to perfusion of ADDLs; arrow denotes TB stimulation. 
Inset calibration: 1 mV, 5 ms, stimulus artefact was removed for clarity. P 
values were calculated using one-way ANoVA and the Tukey–Kramer post 
hoc test. (c) Synaptic field potentials were recorded in vivo from the CA1 area 
of anaesthetized male Wistar rats. In vehicle-injected rats (#first injection 
10 µl i.c.v.; *second injection 5 µl 30 min later), high-frequency stimulation 
(HFS) triggered persistent and stable LTP (black squares, 136 ± 7% at 3 h post 
tetanus, n = 5). In contrast, injection of 5 µl Aβ-containing brain extract 15 min 
before HFS, in animals pre-injected with an IgG1 isotype control antibody 
(30 µg), significantly inhibited LTP (red circles, 106 ± 4%, n = 5, P < 0.05). 
Importantly, injection of the anti-PrPC antibody, ICSM-18 30 min before 
injection of Aβ-containing TBS AD brain TBS extract (15 min before HFS) 
prevented the inhibition of LTP (grey triangles, 136 ± 5%, n = 5). Calibration: 
2 mV, 10 ms. #Refers to injection of ICSM18; *refers to injection of TBS extract 
of human-derived Aβ; arrow denotes HFS. Insets show representative 
electrophysiological traces at the times indicated before (1,3,5) and after 
(2,4,6) conditioning stimulation. Data represent mean ± standard deviation 
and is the average of n = 6 from six individual mice.ARTICLE
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whether this requires in situ Aβ present over longer periods. Previ-
ous studies have shown N-methyl-d-aspartate receptor are involved 
in toxic effects related to ADDLs but appear not to bind directly30. 
Given that PrP has been suggested to interact with NR2D subunits 
and attenuate excitotoxicity31 it is plausible that a number of these 
proteins are involved in Aβ toxicity through similar pathways. In 
that sense, the lack of a vital PrP function would make it a most 
attractive therapeutic target.
In addition, the demonstration that Aβ-mediated inhibition of 
LTP in vivo and in vitro can be blocked by anti-PrP antibodies fur-
ther extends these findings, arguing against the effect in PrP null 
mice being due to unknown protective effects of constitutive PrP 
ablation. That antibodies raised against two structurally and sequen-
tially different regions of the protein are active strongly argues that 
PrP is the target of these antibodies in vivo and that the effect is 
not nonspecific. Furthermore, these same antibodies have already 
been used to successfully treat prion disease in mice without caus-
ing toxic effects15. The PrP:Aβ-binding interaction has been further 
characterized using material of known biological activity and a bio-
physical assay developed to investigate potential therapeutic agents, 
which might efficiently disrupt this interaction. The anti-PrP mono-
clonal antibodies ICSM-18 and 35, already extensively studied in 
vivo in mouse and fully humanized for investigation as putative 
human anti-prion therapeutics, potently inhibit Aβ-induced effects 
on synaptic plasticity both in vitro and in vivo suggesting that the 
humanized versions of these antibodies should be considered for 
potential AD therapeutic trials either individually or in combina-
tion. As both ADDL preparations and Aβ extracted from human 
brain in aqueous buffer are highly heterogeneous, additional studies 
are required to biophysically characterize the key toxic species that 
bind to PrP.
Methods
Materials. Aβ1 − 42 was from California Peptide Research and biotinylated Aβ1 − 42 
with biotin attached to Asp1 using a 6-carbon linker (bAβ1 − 42) was synthesized, 
and purified by Dr James I. Elliott at Yale University (New Haven, CT). Peptide 
masses and purities were determined by electrospray ionization/ion trap mass 
spectrometry and reverse-phase HPLC, respectively. Other reagents were pur-
chased from Sigma Aldrich unless otherwise stated.
Production of ADDL and bADDL preparations. bAβ1 − 42 or Aβ1 − 42 (~1.25 mg) was 
dissolved in HFIP, sonicated and left to stand at room temperature for 1 h.  
The HFIP was evaporated under a stream of dry air/N2 to produce a clear film. The 
peptide film was dissolved in anhydrous dimethylsulphoxide (DMSO) with vigor-
ous vortexing then diluted to 100 µM in phenol red-free Ham’s F12 medium (Pro-
mocell GmbH) and vortexed for 15 s. Samples were incubated at room temperature 
for 16 h. Finally, samples were centrifuged at 14,200 g for 15 min, used immediately 
or snap frozen in liquid N2 and stored at  − 80 °C. Monomeric Aβ1 − 42 was produced 
by dissolving Aβ1 − 42 peptide in 10 mM NaOH (pH 11) for 1 h.
Size-exclusion chromatography. Aliquots (0.5 ml) of freshly prepared 100 µM 
Aβ1 − 42 (10 mM NaOH, pH 11), ADDLs and bADDLs (phenol red-free Ham’s F12 
medium, 2% DMSO) were injected onto a Superdex 75 10/30 column (GE Health-
care) and eluted with PBS at a flow rate of 0.8 ml min − 1 using an AKTA FPLC and 
peptide eultion monitored by absorbance at 280 nm.
Sedimentation velocity analytical ultracentrifugation. Experiments were per-
formed on a Beckman XLI analytical ultracentrifuge (Beckman). Freshly prepared 
100 µM bADDLs (phenol red-free Ham’s F12 medium, 2% DMSO) were centri-
fuged at 201,600 g at 20 °C with absorbance data collected at 278 nm. Sedimenta-
tion velocity data were analysed as described32,33 and graphically presented in the 
standard format with the sedimentation coefficient plotted against the sedimenta-
tion coefficient distribution.
Electron microscopy. For analysis, a 4 µl drop of bADDLs/ADDLs was  
loaded onto negatively glow discharged copper grids, which had been  
previously coated with a continuous carbon film. The sample was left to adhere  
for 30 s and excess solution carefully blotted using grade 4 Whatman paper,  
the sample stained with 2% uranyl acetate (6 µl) for 30 s, blotted and the grid left to 
air dry. Images were recorded on film at a magnification of ×42,986 using an FEI 
Tecnai T12 EM operating at 120 kV. Imaging was done at a defocus range of 700 nm 
to 1 µm and an electron dose of 10–20 electrons per Å2. Films were digitized with a 
step size of 7 µm using a Zeiss SCAI film scanner, giving a pixel size of 1.63 Å.
SDS–PAGE. Aliquots (5 & 10 µl) of 10 µM bADDL and ADDL preparations were 
boiled in sample buffer and electrophoresed on 16% polyacrylamide Tris–tricine 
gels and analysed for Aβ content by comparison to known Aβ standards following 
visualization by silver staining. Alternatively, the ADDLs/bADDLS were diluted 
to 1:10 (1 µM) in sample buffer and used without boiling for western blotting with 
the amino-terminal anti-Aβ antibody, 6E10 (Signet). Immunoreactive bands were 
detected and quantified using a Licor Odyssey imaging system (Licor Biosciences).
Preparation of human AD brain samples. All procedures for use of human tissue 
in this research were approved by a multicentre Research Ethics committee. Three 
brain samples were used for this study: one from a 78-year-old female with a history 
of dementia and confirmed Alzheimer’s disease pathology (from Asterand), a second 
from an 80-year-old female (Queen Square Brain Bank for Neurological Disorders, 
UCL Institute of Neurology) with clinical and pathological diagnoses of AD and the 
other from a cognitively intact 68-year-old female (Queen Square Brain Bank for 
Neurological Disorders, UCL Institute of Neurology). Samples of frozen posterior 
temporal cortex were used to prepare water-soluble Aβ homogenates free from 
membrane-bound or plaque-associated material. The homogenates were dialysed at 
4 °C and stored at  − 80 °C .The amount and form of Aβ present was determined by 
western blotting and quantified by comparison to synthetic Aβ standards34.
Generation of FVB/N congenic PrP knockout line. The FVB/N-Prnpo/o (PrP 
null) congenic line was generated by ten generations of backcrossing ZH1 PrP null 
mice35 to FVB/N followed by genetic testing by Charles River (Margate, UK) using 
84 FVB-specific PCR microsatellite makers covering 19 chromosomes at ~20 cM 
intervals to select breeding pairs positive for 100% of the FVB-specific markers. 
The selected congenic pairs were inter-bred to remove the endogenous murine  
PrP gene and to restore homozygosity of the knockout allele.
In vitro electrophysiology. Two- to four-month-old FVB/N (Harlan, Wyton, 
UK) or PrP null mice (FVB/N-Prnpo/o, MRC Prion Unit) were used to study the 
effects of bADDLs and Aβ-containing extracts of human brain. In addition, 2- to 
3-month-old C57BL/6J mice (Charles River, Margate, UK) were used to examine 
the effects of bADDLs/ADDLs and the anti-PrP antibodies, ICSM-18 and ICSM-
35. Male mice were used in all experiments to eliminate any gender bias and were 
group housed under normal 12-h light–dark conditions. In all cases, mice were 
anaesthetized with isoflurane/O2 and decapitated. The brain was rapidly removed 
and immersed in ice-cold sucrose-based artificial cerebrospinal fluid before  
parasagital sections (350 µm) were prepared on a Leica VT1000S vibratome 
(Leica). Slices were allowed to recover for at least 90 min before being submerged 
in a recording chamber and perfused with oxygenated artificial cerebrospinal 
fluid at 30 °C. Extracellular field excitatory postsynaptic potentials (fEPSPs) were 
recorded from stratum radiatum of area CA1 of the hippocampus. Following 
baseline recording, LTP was induced by theta-burst stimulation (ten bursts of four 
stimuli at 100 Hz, with an interburst interval of 200 ms) given at baseline intensity. 
In experiments using bADDLs/ADDLs or TBS extracts of human brain, the sample 
was added to the perfusate 30 min before induction of LTP. Where a combina-
tion of ADDLs and anti-PrP antibodies were used, the antibody was added to the 
perfusate 20 min before the ADDLS. Once added to the perfusate, ADDLs, brain 
samples and/or antibodies were present for the duration of the experiment.
In vivo electrophysiology. In vivo studies on urethane (1.5 gm kg − 1 intraperito-
neal) anaesthetized male adult Wistar rats (250–300 g) were approved by Trinity 
College Dublin’s Ethical Review Committee and by the Department of Health, 
Republic of Ireland. Single-pathway recordings of fEPSPs were made from the stra-
tum radiatum in the CA1 area of the right hippocampal hemisphere in response to 
stimulation of the ipsilateral Schaffer collateral-commissural pathway. Test fEPSPs 
were evoked at a frequency of 0.033 Hz and at a stimulation intensity adjusted 
to elicit a fEPSP amplitude of 50% of maximum. LTP was induced following a 
HFS consisting of 10 bursts of 20 stimuli with an inter-stimulus interval of 5 ms 
(200 Hz), and an inter-burst interval of 2 s. A stainless-steel guide cannula was 
implanted above the right lateral ventricle to allow i.c.v. injection of human brain 
samples, control solution and/or anti-PrP antibody (ICSM18). Verification of the 
placement of the cannula was performed post-mortem by checking the spread of 
i.c.v.-injected ink dye.
Protein expression and purification. Constructs of human PrP were expressed36 
and purified37 as described previously. Protein quality was confirmed by  
SDS–PAGE, MALDI–TOF mass spectrometry and circular dichroism spectroscopy.
DELFIA. Human PrP (10 mM sodium carbonate, pH 9.6) was bound to medium 
binding 96-well white plates (Greiner) and blocked with BSA. If required, anti-
body was then incubated for 1 h. Different preparations of Aβ1 − 42 were incubated 
for 1 h. Aβ was detected by 6E10 for 1 h and incubated for 30 min with DELFIA 
Eu-N1 anti-mouse antibody before enhancing with DELFIA enhancement 
solution38. Biotinylated Aβ was detected by DELFIA Eu-N1 streptavidin before 
enhancing with DELFIA enhancement solution. For PrP antibody-binding experi-
ments, ICSM antibodies (D-Gen Ltd) were incubated for 30 min with DELFIA Eu-
N1 anti-mouse antibody before enhancing with DELFIA enhancement solution. 
Binding of antibodies to PrP was detected by incubation for 30 min with DELFIA ARTICLE     
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Eu-N1 anti-mouse antibody before enhancing with DELFIA enhancement solu-
tion. Plates were scanned for time-resolved fluorescence intensity using a Perkin-
Elmer EnVision plate reader (Perkin-Elmer). Binding constants were calculated 
using a 1-site Langmuir isotherm and were tested for tight-binding characteristics. 
This ensures a true Kd can be measured and that direct saturation of the protein 
surface as soon as stoichiometric quantities of peptide are added has not occurred.
Molecular modelling. A model of the full ISCM-18 antibody complex with human 
PrPC
119 − 231 was constructed by superimposing PrP-Fab complex (2W9E) onto the 
Fab domains of a full human IgG antibody structure (1HZH). The ADDL particle 
was constructed as described in the Supplementary Methods. The N-terminus of 
the PrPC molecule, taken from the Fab crystal structure complex (2W9E), was ex-
tended back to residue 95 as an unstructured polypeptide. Copies of this molecule 
were manually docked to the surface of the ADDL particle. Molecular graphics 
and model building were performed using InsightII (2005) and energy calculations 
using Discover 2.98 (Accelrys).
Full methods describing the preparation of ADDL/bADDL, human AD brain 
samples, the in vitro and in vivo electrophysiology, DELFIA and molecular model-
ling can be found in the Supplementary Methods. 
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